Skip to main content

pentostatin

Generic: PENTOSTATIN·Brand: NIPENT, Nipent, PENTOSTATIN

pentostatin: 3 clinical trials tracked.

pentostatin evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about pentostatin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Clinical Trials (3)

A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Severe Aplastic Anemia Patients With COH-MC-17: A Non-Myeloablative/ Reduced-Intensity, Conditioning Regimen and CD4+ T-Cell-Depleted Haploidentical Hematopoietic Transplant

NCT05757310·Phase 1
Recruiting

Primary endpoint: Incidence of adverse events

Interventionalopen6 targetStarted 2024-11Completion 2027-061 site · United StatesCity of Hope Medical Center

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)

NCT03112603·Phase 3·INCY
Completed

Primary endpoint: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit

InterventionalRandomizedopen330 enrolledStarted 2017-06Completion 2022-1250 sites · Australia, Austria, Belgium, United StatesIncyte Corporation

Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

NCT03077542·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: Percentage of Participants Who Have Not Rejected Their Stem Cell Graft and Who Are Without Severe Graft-versus-host Disease Following Stem Cell Transplant

Interventionalopen57 targetStarted 2017-04Completion 2026-081 site · United StatesNational Heart, Lung, and Blood Institute (NHLBI)